Navigation Links
Pepscan Achieves First Milestone in Research Collaboration With Genmab
Date:3/10/2009

LELYSTAD, The Netherlands, March 10 /PRNewswire/ -- Pepscan Therapeutics (Pepscan) today announced that it has earned a milestone payment from Genmab A/S. The milestone payment arises from an ongoing Research Collaboration aimed at identifying human antibodies against intractable targets. Pepscan is responsible for using it CLIPS(TM) technology to generate immunogens that mimic the protein targets to induce human antibodies against these intractable targets.

Under the terms of the collaboration agreement, Pepscan is eligible to receive additional payments from Genmab upon the achievement of certain development and regulatory milestones. Pepscan is also eligible to receive royalties on potential sales of any therapeutics developed as a result of the collaboration.

"The achievement of this milestone further validates Pepscan's CLIPS(TM) platform", said Rob Meloen, CSO of Pepscan Therapeutics. "We are pleased to see the significant progress that has been made in the collaboration with Genmab."

About Intractable Targets

"Intractable" Targets are drug targets that would be desirable to address with monoclonal antibodies but are inaccessible with alternative commercially available technologies. This can be due to the fact that target proteins are buried to a large extent very close to the cell surface or in the cell membrane or due to poor immunogenicity of the protein or desirable epitopes.

About Pepscan Therapeutics

Pepscan Therapeutics is a product focused immunotherapy company based in the Netherlands. It has developed a pipeline of therapeutic vaccine and antibody programs of which the most advanced is in Phase II clinical testing. Pepscan's proprietary and innovative CLIPS(TM) technology has proven to yield functional antibodies reactive with a range of complex proteins, including GPCRs.

About CLIPS(TM) Technology

Chemically Linked Immunogenic Peptides on Scaffolds (CLIPS(TM)) is a technology to present one or more peptides in a structurally constrained configuration. These molecules behave as functional mimics of complex protein domains that serve as superior immunogens in the induction and selection of antibodies against disease relevant protein targets. This is especially valuable in the case of proteins that are inaccessible as recombinant proteins (e.g. GPCRs, ion channels, patented proteins).


'/>"/>
SOURCE Pepscan Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
2. Pharsight Achieves First License Sale for Public-Source Database
3. GenoLogics Geneus Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform
4. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
5. Signalife Achieves $1.98 Million Sales Orders Thus Far
6. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
7. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
8. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
9. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
10. NOLabs AB Achieves Break-Through in Fight Against MRSA-Bacteria
11. BIAS Achieves Certified Advantage Partner Level in Oracle PartnerNetwork
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Cambridge Semantics, the ... technology, today announced that it has been named to The Silicon Review’s “20 Fastest ... and other markets, Cambridge Semantics serves the needs of end users facing some of ...
(Date:4/27/2016)... ... April 27, 2016 , ... Most consumers engage with biometrics ... for secure access, voice recognition for hands-free communication, and facial recognition to help ... biometrics technology today. But if they asked Joey Pritikin, Vice President of ...
(Date:4/27/2016)... ... April 27, 2016 , ... The Board of Directors ... of John Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from Alexion ... commercial leaders responsible for the commercialization of multiple orphan drug indications. Mr. ...
(Date:4/27/2016)... ... April 27, 2016 , ... A compact PET scanner ... and MRI (Magnetic Resonance Imaging) in existing third-party MRI systems. PET and MRI ... small animal subjects. Simultaneous PET/MRI imaging offers a solution to many challenges that ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
Breaking Biology News(10 mins):